- Barrons.com•1 hour ago
Despite yesterday's news about its NASH treatment, Gabelli's Jing He argues that Gilead Sciences' (GILD) still needs an acquisition. She explains why: On October 21, 2016, Gilead announced PhII results ...
- Business Insider•2 hours ago
Close to 8% of the Georgian population is living with hepatitis C, an infection that can...
- Barrons.com•3 hours ago
Yesterday, Gilead Sciences (GILD) reported Phase 2 trial data on its NASH treatment that was good enough to move on to Phase 3 (even if everyone wasn't convinced). RBC's Michael Yee and team consider the ...
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||74.29 x 1100|
|Ask||74.30 x 400|
|Day's Range||73.78 - 74.94|
|52wk Range||72.21 - 111.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.52|
|Avg Vol (3m)||10,609,706|
|Dividend & Yield||1.88 (2.56%)|